Share ownership Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 07:21:07 10/07/2025 pm IST			5-day change	1st Jan Change
1,383.50 ^DKK	+0.87%		+6.93%	-7.44%

01/07	Genmab Announces Changes to Its Executive Committee	CI
01/07	Genmab's Chief Legal Officer Steps Down; Successor Named	MT

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,61,87,186	6,34,98,948 ( 95.94 %)	26,47,007 ( 3.999 %)	95.94 %

Major shareholders: Genmab A/S

Name	Equities	%	Valuation
Wellington Management Co. LLP 4.89 %	32,37,113	4.89 %	670 M kr
GENMAB A/S 4.006 %	26,51,727	4.006 %	549 M kr
Jan van de Winkel 0.9526 %	6,30,588	0.9526 %	130 M kr
Nykredit Bank A/S (Investment Management) 0.4979 %	3,29,596	0.4979 %	68 M kr
Danske Bank A/S (Investment Management) 0.3315 %	2,19,426	0.3315 %	45 M kr
Amundi Asset Management SASU (Investment Management) 0.2998 %	1,98,479	0.2998 %	41 M kr
Robert W. Baird & Co., Inc. (Equity) 0.236 %	1,56,210	0.236 %	32 M kr
State Street Global Advisors Ltd. 0.1942 %	1,28,579	0.1942 %	27 M kr
Candriam SCA 0.159 %	1,05,239	0.159 %	22 M kr
Sjunde AP-fonden 0.1456 %	96,412	0.1456 %	20 M kr
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
AllianceBernstein LP 2.225 %	1,47,25,158	2.225 %	304 M kr
Orbis Investment Management Ltd. 0.8628 %	57,10,741	0.8628 %	118 M kr
Citadel Securities GP LLC 0.6688 %	44,26,654	0.6688 %	91 M kr
Aperio Group LLC 0.5116 %	33,85,857	0.5116 %	70 M kr
Harding Loevner LP 0.4353 %	28,80,826	0.4353 %	60 M kr
Eaton Vance Management 0.4289 %	28,38,928	0.4289 %	59 M kr
Renaissance Technologies LLC 0.3418 %	22,62,350	0.3418 %	47 M kr
Marshall Wace LLP 0.3296 %	21,81,510	0.3296 %	45 M kr
Two Sigma Advisers LP 0.2982 %	19,73,700	0.2982 %	41 M kr
Two Sigma Investments LP 0.287 %	18,99,766	0.287 %	39 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	95.1%
Other	11.95%
Genmab A/S	4.01%
Individuals	1.03%
SEI Investments Co.	0.09%
Fifth Third Bancorp	0.06%
Skandinaviska Enskilda Banken AB	0.04%
Regions Financial Corp.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	89.14%
Bermuda	8.63%
Denmark	5.17%
United Kingdom	4.89%
Individuals	1.03%
France	0.65%
Norway	0.47%
Ireland	0.34%
Canada	0.3%
Sweden	0.24%
Switzerland	0.23%
Luxembourg	0.22%
Germany	0.22%
Italy	0.19%
Finland	0.18%
China	0.07%
Hong Kong	0.06%
Australia	0.05%
Belgium	0.05%
Cayman Islands	0.05%
Singapore	0.02%
Portugal	0.02%
Japan	0.02%
Netherlands	0.01%
Philippines	0.01%
Spain	0.01%
South Africa	0.01%
Mexico	0.01%
Austria	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,638

Sector

Biotechnology & Medical Research

Calendar

07/08 - Q2 2025 Earnings Release

More about the company